Mercury Laboratories Ltd

Mercury Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 28 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Mercury Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 28 July 2026, reflecting a nuanced shift in its financial, quality, valuation, and technical parameters. Despite ongoing challenges in quarterly financial performance, the company’s quality metrics have improved to an average grade, while technical indicators suggest a mildly bearish outlook. This article analyses the key factors driving this rating change and what it means for investors navigating the Pharmaceuticals & Biotechnology sector.

Mercury Laboratories Ltd has seen its quality grade improve from below average to average, reflecting a nuanced shift in its business fundamentals. While certain key metrics such as return on capital employed (ROCE) and return on equity (ROE) show moderate strength, other indicators like earnings growth and debt levels present a more complex picture for investors navigating the pharmaceuticals and biotechnology sector.

Mercury Laboratories Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹97.00 crores, reported deeply disappointing results for Q1 FY27, with net profit collapsing 69.07% quarter-on-quarter to ₹0.30 crores from ₹0.97 crores in the previous quarter. The stock, trading at ₹835.00, has declined 4.02% over the past year, significantly underperforming its pharmaceuticals sector peers who gained 11.43% during the same period.

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 22 July 2026. This adjustment reflects a combination of deteriorating technical indicators, stagnant financial performance, and weak long-term fundamentals, despite some attractive valuation metrics. The downgrade signals caution for investors amid mixed signals from the company’s operational and market trends.

Mercury Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 July 2026, driven primarily by a shift in technical indicators despite persistent challenges in its financial performance and long-term fundamentals. This nuanced change reflects a complex interplay of quality, valuation, financial trends, and technical signals that investors should carefully consider.

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Strong Sell as of 6 July 2026. This change is primarily driven by an improvement in valuation metrics, despite ongoing challenges in financial trends and quality parameters. The company’s Mojo Score now stands at 28.0, reflecting a cautious stance amid mixed fundamentals and technical signals.

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 1 July 2026. This change is primarily driven by a significant improvement in valuation metrics, even as the company’s financial performance remains flat and its long-term fundamentals continue to show weakness.

Mercury Laboratories Ltd has witnessed a notable improvement in its valuation parameters, shifting from an attractive to a very attractive rating, despite a challenging sector environment. This micro-cap pharmaceutical player now presents a compelling price proposition relative to its historical averages and peer group, signalling a potential inflection point for investors seeking value in the Pharmaceuticals & Biotechnology sector.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 27 May 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 28 June 2026, providing investors with the latest view of the company’s position.

Mercury Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Mercury Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, marking a significant shift from its previously positive growth trajectory. Despite a higher profit after tax (PAT) for the nine-month period, the company’s quarterly operating profit and margins have contracted sharply, prompting a downgrade in its Mojo Grade to Strong Sell.

Mercury Laboratories Ltd., a Mumbai-based pharmaceutical company, reported concerning results for Q4 FY26 (January-March 2026), with net profit rising 10.81% quarter-on-quarter to ₹1.23 crores but declining 1.06% year-on-year from ₹1.11 crores. The ₹93.00 crore market capitalisation company faced significant margin pressures as operating profitability deteriorated to its lowest level in recent quarters, raising questions about the sustainability of its business model in an increasingly competitive pharmaceutical landscape.